Work

Abstract PS4-04-30: Discovery of NKT5097: a first-in-class, highly potent and selective, orally bioavailable CDK2/4 dual degrader for cancer therapy

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps4-04-30

Authors: K. Liu, J. Geng, Z. Yu, Y. Yeh, H. Wei, W. Sun, W. Li, J. Lu, J. Deng, C. Yang, L. Geng, X. Luo, Y. Liang, Z. Liu, Z. Gao, Y. Lou

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129659420

Cites:

Cited by: 1

Related to: